A Phase 2 interventional study of Chloroprocaine 1% Injectable Solution and Chloroprocaine 2% Injectable Solution in Hernia, Inguinal and Flat Foot, sponsored by Sintetica SA. Completed at 9 sites in 2 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-03-23.
Sponsored by Sintetica SA · Phase 2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Hernia, Inguinal with a site in Italy — 3 open to participants now, 3 under way, none of them phase 3. Hernia, Inguinal · Italy.
Among the 19 studies in Hernia, Inguinal with a site in Italy, this one is the 5th largest by enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2019, is the only one in phase 2, and was the 10th registered.
545 studies on the registry are indexed under Hernia, Inguinal; 93 are open to participants now.
Browse Hernia, Inguinal studies →3 of the 19 studies in Hernia, Inguinal with a site in Italy are open now. Recruiting first, the newest first:
CMR Surgical Ltd · Sites in Italy, Spain
Ages 22+
University of Roma La Sapienza · Sites in Italy
Ages 18+
University of Palermo · Sites in Italy
Ages 18–85 · Men only
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 56 Hernia, Inguinal studies recruiting now, 30 (54%) set no upper age limit and 17 (30%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.
This study: Up to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 164 is above the median of 90 across 397 interventional studies indexed under Hernia, Inguinal.
Median enrollment 116 across the 14 interventional studies, 71 across the 5 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 19 have an industry lead sponsor. The 10 most frequent:
Sintetica SA is the lead sponsor of 11 studies on the registry; none are open to participants now.
Sintetica SA has 1 study filed under Hernia, Inguinal — fewer than ten, so there is no comparison to draw.
1 of the studies in Hernia, Inguinal with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07316517CMR Surgical LtdVersius Clinical Study in Robot Assisted Inguinal Hernia Repair Surgery | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Hernia, Inguinal with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Randomized, multi-center, double-blind, two-armed, parallel active groups, prospective trial to evaluate the efficacy and safety of local anesthetic Chloroprocaine at two different concentrations ( at 1% and 2%) in a pediatric population subjected to peripheral nerve block due to Inguinal hernia repair or Flat foot surgery. The present Protocol is part of an extensive Pediatric Investigational Plan (PIP) in the contest of the marketing authorization application of chloroprocaine use for perineural block. The PDCO has adopted a positive opinion.
Randomized, multi-center, double-blind, two-armed, parallel active groups, prospective trial, to evaluate, in pediatric population undergoing Flat Foot surgery or Inguinal hernia repair, the efficacy and safety of chloroprocaine 1% and 2% for peripheral nerve block (PNB) based on concentration-response relationships. The present protocol is part of an extensive Pediatric Investigational Plan (PIP) which has been submitted to the Paediatric Committee (PDCO) of the European Medicine Agency (EMA)in the contest of the marketing authorization application of chloroprocaine use for perineural block. The PDCO has adopted a positive opinion on both the PIP and the present clinical protocol.
Chloroprocaine Hydrochloride 1% Sintetica is currently marketed in 9 European countries as intrathecal (spinal) anesthetic in adults where the planned surgical procedure is not expected to exceed 40 minutes. Since 2015, the Marketing Authorization in Switzerland has been extended to chloroprocaine HCl 20 mg/mL and 30 mg/mL solutions for injection, for local anesthesia by infiltration, for PNB and epidural block, respectively. Regional analgesia, and specifically PNB, is an acceptable means of providing intraoperative anesthesia and postoperative analgesia in neonates, infants, and children while decreasing the use of systemic opioids and avoiding opioid-related adverse effects. With the advent of ultrasound and improvements in equipment in the last decade, the utilization of PNB in children has increased tremendously.
Flat Foot and inguinal hernia repair have been considered the ideal surgeries for testing the clinical efficacy and safety of chloroprocaine since they are short procedures with low postoperative pain that only require a short- to intermediate-acting agent. The study consists of a treatment period of 1 day and of a single perineural injection, administered through ultrasound-guided technique in order to avoid the risk of chloroprocaine IV injection. A total of 174 (87 per treatment group, allocated to 1% or 2% arm in a ratio of 1:1) male and female paediatric patients (age range from birth to \<18 years) undergoing Flat Foot surgery or Inguinal hernia repair, planned for peripheral nerve block anaesthesia and equally distributed within the two surgical procedures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male and female paediatric patients from birth to \<18 years scheduled for:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
Drug: Chloroprocaine 1% Injectable Solution
All the eligible patients will be administrated by Chloroprocaine 2 % according to the randomization criteria.
Drug: Chloroprocaine 2% Injectable Solution
All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
Also known as: ARM 1
All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
Also known as: ARM 2
Overall proportion of patients, in each of the two dosage level groups, not requiring rescue anesthesia during surgery.
The primary efficacy endpoint of the study will be represented by the overall proportion of patients, in each of the two dosage level groups, not requiring rescue anesthesia during surgery.
Time frame: Visit 2 (Day 1; surgery/discharge)
Proportion of patients, in both of the two dosage level groups, not requiring rescue anaesthesia (fentanyl) during the two surgical procedures separately
Proportion of patients, in both of the two dosage level groups, not requiring rescue anaesthesia (fentanyl) during the two surgical procedures separately; Time to onset of sensory block, defined as the time period from completion of the injection (time 0 min) to the achievement of complete sensory block, assessed by pinprick test associated with heart rate measurement, and evaluated for both surgeries; Time to regression of motor block evaluated in 'calcaneo stop' surgery only and assessed by a grade I of the standard Bromage scale (i.e. free movement of legs and feet). Pain intensity evaluated five times in the first 3 hours after patient's awakening andduring the home discharge visit (V2). The technique and appropriate scale for pain measurement are age-dependent therefore, different tools will have to be used for the evaluation: COMFORT scale for patients \<2 months of age; FLACC scale for patients aged \_ 2 months \_ 6 years; Wong-Baker scale for patients over 6 years of age
Time frame: Visit 2 (Day 1; surgery/discharge); FU phone call I( 24 hrs from Visit 2); FU phone call II (7 days from Visit 2)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — It is not yet known if there will be a plan to make IPD available.
Ran from Feb 2019 to primary completion in Oct 2025, 80 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chloroprocaine
Sintetica SA